Turnaround times
The quoted turnaround time is from sample receipt in the laboratory, to results authorisation in the Laboratory Information Management system. The times do not include transport of specimen to the laboratory or the administrative process to print and post/email reports. Service users must allow for transport and reporting time when ordering tests.
Clinical background:
Prothrombin G20210A is a variant form of human factor II that is associated with an increased risk of thrombosis. Due to the mutation, in which guanine is replaced with adenine at position 20210 of the Prothrombin gene increased levels of plasma prothrombin are seen, resulting in an increased thrombotic risk. Most individuals do not suffer thrombosis in their lifetime, but there is a proven link to increased risk
Specimen container paediatric:
Light blue- sodium citrate (semi transparent cap)
Specimen container adult:
Light blue- sodium citrate
Minimum volume paediatric:
Single whole blood sample
Minimum volume adult:
Single whole blood sample
Sample stability:
7 days @ 4°C
Transport requirements:
Samples should be transported to the laboratory without delay
Freq analysis:
Fortnightly or urgent as required
Add on test:
[email protected] (external)
Quality assurance:
UK NEQAS Blood Coagulation
Reference ranges:
Prevalence in Caucasian population
2%Prevalence in patients presenting with DVT or PE 6%
Other info:
Thrombotic risk
Heterozygote 2.5 fold increase
Homozygote 20 fold increase
Increased risk of thrombosis in pregnancy
Heterozygotes show a 10 fold increased risk with Oestrogen containing oral contraception
Combined Prothrombin G20210A and Factor V Leiden (R506Q) mutations show a 15 fold increased thrombotic risk